Time to unshackle the medical treatment of obesity in the NHS.

Autor: Ansari S; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom., Mazaheri T; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom., O'Donnell K; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom., Waite M; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom., Cann A; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom., Abdel-Malek M; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom., Boyle L; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Centre for Obesity, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, United Kingdom., Tweedlie L; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Psychological Medicine Department, West London NHS Health Trust, London UB2 4SD, United Kingdom., Scholtz S; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom; Psychological Medicine Department, West London NHS Health Trust, London UB2 4SD, United Kingdom., Hameed S; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom., Izzi-Engbeaya C; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom., Chahal H; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom., Tan T; Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom. Electronic address: tricia.tan@nhs.net.
Jazyk: angličtina
Zdroj: Clinical medicine (London, England) [Clin Med (Lond)] 2024 May; Vol. 24 (3), pp. 100206. Date of Electronic Publication: 2024 Apr 21.
DOI: 10.1016/j.clinme.2024.100206
Abstrakt: Obesity affects one in four people in the United Kingdom and costs the National Health Service (NHS) ∼£6.5 billion annually. The glucagon-like peptide-1 (GLP-1) receptor analogues, such as once-daily subcutaneous Liraglutide 3.0 mg (Saxenda®) and once-weekly subcutaneous Semaglutide 2.4 mg (Wegovy®), were approved by the National Institute of Health and Care Excellence (NICE) as a treatment for obesity and funded by the NHS for 2 years. Our local data shows that Saxenda is effective at reducing body weight and glycaemia in people with obesity and diabetes; however, the supply issues of GLP-1 receptor analogues have contributed to the unavailability of Saxenda and Wegovy in our service. Our patients are devastated that they cannot access NICE-approved GLP-1 receptor analogues for obesity. The 2-year GLP-1 receptor analogue treatment limit for obesity alongside a lack of funded NHS services and supply issues represent barriers to treatment for people living with obesity who have clear medical indications.
Competing Interests: Declaration of competing interests Prof Tricia Tan is a shareholder in, and consultant for Zihipp Ltd, an Imperial College spinout company that is developing gut hormone analogues for treatment of obesity.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: